• BFH772 (VEGFR2 inhibitor): Protocols, QC, and Workflow Guida

  2026-08-06

  BFH772 is a potent, selective VEGFR2 inhibitor designed for researchers requiring precise inhibition of VEGFR2-driven angiogenesis, especially in tumor model studies. It is optimal for workflows emphasizing kinase selectivity and organic solvent compatibility, but is not suitable for protocols requiring water solubility or long-term solution storage.

• LY2109761: Dual TGF-β Kinase Inhibition in Fibrosis and Onco

  2026-08-05

  Explore how LY2109761, a potent TGF-β receptor type I and II dual inhibitor, advances fibrosis and cancer research through Smad2/3 phosphorylation blockade and unique preclinical outcomes. This article delivers new practical and mechanistic insights for experimental design.

• Docetaxel Workflows: Precision in Cancer Chemotherapy Resear

  2026-08-05

  Docetaxel (Taxotere) stands apart as a microtubule stabilization agent, enabling robust, reproducible cancer chemotherapy research. This guide delivers stepwise workflows, critical troubleshooting, and experimental insights for maximizing assay impact and decoding resistance mechanisms.

• Calpeptin as a Calpain Inhibitor: Innovations in Fibrosis an

  2026-08-04

  Discover how Calpeptin, a potent calpain inhibitor, uniquely advances fibrosis and extracellular vesicle (EV) research. This article provides a deep scientific analysis, practical assay guidance, and new perspectives distinct from prior work.

• Diminazene Aceturate: Applied Protocols in Parasite and ACE2

  2026-08-04

  Diminazene Aceturate stands out for its dual functionality in trypanosome parasite and ACE2 pathway research, enabling advanced studies in both infectious disease and cardiovascular models. This guide covers stepwise workflows, troubleshooting strategies, and novel applications based on recent mitochondrial biogenesis findings.

• WY-14643 (Pirinixic Acid): PPARα Agonism in Tumor Microenvir

  2026-08-03

  Discover how WY-14643 (Pirinixic Acid) extends beyond metabolic assays to illuminate PPARα’s role in tumor microenvironment modulation and advanced metabolic disorder research. Explore unique insights, protocol guidance, and translational outlooks for next-generation studies.

• Diminazene Aceturate: Protocol Advances in Parasite and ACE2

  2026-08-03

  Diminazene Aceturate stands at the forefront of both trypanosome parasite research and mitochondrial biogenesis studies through ACE2 activation. This article translates recent mechanistic breakthroughs into actionable workflows, protocol enhancements, and troubleshooting strategies for high-reproducibility scientific discovery.

• Captopril: ACE Inhibitor Benchmarks in Hypertension Research

  2026-08-02

  Captopril is a potent ACE inhibitor with an IC50 of 6 nM, widely validated for hypertension research and apoptosis induction in cancer models. Its selectivity and robust solubility profile make it a benchmark for translational workflows. APExBIO provides Captopril with >96.5% purity, enabling reproducible results across cardiovascular and bradykinin-mediated gastrointestinal studies.

• Optimizing hiPSC-Derived Platelet Production via Small Molec

  2026-08-01

  This study presents an optimized protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs) by leveraging small molecule modulators and refined culture techniques. The approach increases yield, reduces costs, and accelerates differentiation, with direct implications for scalable platelet manufacturing and cell therapy applications.

• circHIF1A/miR-486-5p/GRHL2 Axis Drives LUAD Progression via

  2026-07-31

  This study delineates how circHIF1A orchestrates lung adenocarcinoma (LUAD) progression by sponging miR-486-5p, thereby upregulating GRHL2 and promoting macrophage M2 polarization. The findings reveal a pivotal ceRNA network shaping tumor microenvironment and identify the circHIF1A/miR-486-5p/GRHL2 axis as a promising biomarker and therapeutic target.

• Morning Exercise Accelerates Endurance Adaptation in Mice

  2026-07-31

  The reference study demonstrates that endurance training performed in the morning (early active phase) leads to more rapid and efficient performance adaptations in mice, compared to afternoon training. These findings highlight the critical influence of exercise timing on metabolic adaptation and inform both experimental design and translational research strategies.

• Calpeptin: Calpain Inhibitor Strategies for Fibrosis Researc

  2026-07-30

  Calpeptin offers nanomolar potency and proven selectivity as a calpain inhibitor, empowering advanced pulmonary fibrosis and cancer research. This guide translates recent breakthroughs and experimental know-how into actionable protocols, troubleshooting insights, and comparative advantages.

• Captopril as a Precision ACE Inhibitor for Translational Res

  2026-07-30

  Captopril enables targeted ACE inhibition for both hypertension and oncology research, facilitating reproducible results across cardiovascular and cancer cell models. This article delivers advanced workflow tips, contextual troubleshooting, and a translational bridge with actionable insights from bradykinin receptor modulation.

• Immobilized Microalgae Extracts Advance Antioxidant Packagin

  2026-07-29

  This study demonstrates a nearly twofold increase in biomass and a 170% boost in antioxidant polysaccharide yield by immobilizing Chlorella sp. in a silk fibroin–reinforced alginate matrix. The resulting extracts deliver strong, thermally stable antioxidant activity and significantly enhance the performance of biodegradable food packaging films.

• Honokiol as a Precision NF-κB Pathway Inhibitor in T-cell Me

  2026-07-29

  Honokiol, a potent small molecule from APExBIO, empowers researchers to dissect immunometabolic reprogramming and tumor microenvironment dynamics with unmatched selectivity. Its ability to block NF-κB activation and scavenge reactive oxygen species makes it a cornerstone for advanced inflammation and cancer research workflows.

7729 records 4/516 page Previous Next 12345 下5页 Last page